Mutated P450 Enzyme Enhancing Steroid Hormone Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biotechnological and industrial use of cytochrome P450 monooxygenases is hindered by low enzymatic activity and difficulties in mimicking the mitochondrial environment in recombinant systems, limiting the efficient production of steroid hormones like pregnenolone, which is crucial for various drugs.
Innovation Solution
A new P450scc polypeptide with specific mutations, including a threonine at position 225 and an aspartic acid at position 289, is developed, enhancing enzymatic activity for substrate conversion into steroid hormones, and is used in genetically engineered microorganisms to produce steroid hormone precursors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mitochondrial P450s are used in recombinant systems, then specific steroid synthesis reactions can be performed, but the mitochondrial environment is difficult to mimic leading to low enzymatic activity
Solution Approach 1:
The invention extracts the P450scc enzyme from its native mitochondrial context and expresses it as a recombinant protein in bacterial systems (E. coli). This extraction allows the enzyme to function without requiring the complex mitochondrial environment, electron transport chains, or associated proteins, thereby simplifying the system while maintaining catalytic function for steroid synthesis.
Solution Approach 2:
The invention uses a simplified electron donor system (NADPH with soluble electron transfer proteins) as an intermediary to replace the complex mitochondrial electron transport chain. This mediator approach provides the necessary reducing equivalents for P450 catalysis without requiring the full mitochondrial apparatus, thus improving enzymatic activity while reducing system complexity.
2Ease of operation
If P450scc is targeted to yeast mitochondria, then proper targeting is achieved, but substrate conversion into pregnenolone fails due to absence of substrate and/or improper folding
Solution Approach 1:
Instead of targeting P450scc to mitochondria and hoping for substrate availability and proper folding, the invention inverts the approach by expressing the enzyme in bacterial cytoplasm where substrate (cholesterol) can be readily supplied and the enzyme can properly fold in the bacterial environment. This inversion of localization strategy resolves both the targeting and productivity issues.
Solution Approach 2:
The recombinant P450scc system is designed to be self-sufficient by co-expressing all necessary components (P450scc, electron transfer proteins, and substrate supply pathways) in a single bacterial host. This self-service approach eliminates the need for complex inter-organellar substrate transfer and folding assistance that would be required in eukaryotic systems.
3Ease of manufacture
If triple fusion of P450scc, Fdx1 and FdxR is performed, then a functional protein is obtained, but efficacy is low compared to bona fide polypeptide and cannot be used at industrial scale
Solution Approach 1:
The invention segments the fused triple protein construct into separate, independently expressed components (P450scc, Fdx1, and FdxR expressed as separate proteins). This segmentation allows each component to fold and function optimally independently, while still working together in the same cellular compartment, thereby improving overall efficacy for industrial-scale production.
Solution Approach 2:
The invention changes the structural parameter from a fused polypeptide chain to separate protein entities that interact through diffusion and binding. This parameter change from covalent linkage to non-covalent association improves the flexibility and efficacy of the enzyme complex, enabling industrial-scale application while maintaining functional integrity.
4Productivity
If conventional P450scc is used, then substrate conversion occurs, but enzymatic activity is insufficient for optimized production of steroid hormones
Solution Approach 1:
The invention introduces specific amino acid mutations in P450scc (e.g., R225T, N289D) that change the enzymatic parameters including substrate affinity (Km) and catalytic rate (kcat). These parameter changes through rational mutagenesis enhance the enzyme's activity and efficiency, enabling optimized steroid hormone production while maintaining reliability.
Solution Approach 2:
The invention creates optimized copies of P450scc with improved properties through site-directed mutagenesis. These copied enzymes retain the core catalytic function but possess enhanced kinetic parameters and stability, allowing for reliable and productive steroid hormone synthesis at industrial scales.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated P450 enzyme exhibits significantly improved monooxygenase activity, enabling efficient conversion of substrates like cholesterol into pregnenolone, suitable for industrial-scale production of steroid hormones.
Implementation Method 1
P450scc (Side Chain Cleaving enzyme), encoded by the CYP11A1 gene, which cleaves the cholesterol side chain thus transforming cholesterol into pregnenolone by two consecutive hydroxylations and a final cleaving
Implementation Method 2
The mutated P450 enzyme exhibits significantly improved monooxygenase activity, enabling efficient conversion of substrates like cholesterol into pregnenolone
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention pertains to an isolated P450 enzyme comprising or consisting of an amino acid sequence at least 80% identical to SEQ ID NO: 1, wherein said sequence comprises a threonine at position corresponding to position 225 and/or an aspartic acid mutation at position corresponding to position 289. The invention also concerns an isolated nucleic acid comprising a sequence encoding said enzyme, a vector comprising said nucleic acid, and a host cell containing said nucleic acid or said vector. Methods for preparing said enzyme and methods for producing steroid hormone precursors using the enzyme or the host cells featured in the invention are also provided.